



Europäisches Patentamt  
European Patent Office  
Office européen des brevets



(11) Publication number:

**0 496 973 A2**

(12)

## EUROPEAN PATENT APPLICATION

(21) Application number: **91120396.6**

(51) Int. Cl.<sup>5</sup>: **C12N 15/18, C07K 13/00,  
C07K 3/08**

(22) Date of filing: **28.11.91**

(30) Priority: **30.11.90 US 621656**

(43) Date of publication of application:  
**05.08.92 Bulletin 92/32**

(84) Designated Contracting States:  
**AT BE CH DE DK ES FR GB GR IT LI LU NL SE**

(71) Applicant: **BIO-TECHNOLOGY GENERAL  
CORPORATION**  
**1250 Broadway**  
**New York NY 10001(US)**  
Applicant: **AMERICAN CYANAMID COMPANY**  
**1937 West Main Street P.O. Box 60**  
**Stamford Connecticut 06904-0060(US)**

(72) Inventor: **Fischer, Meir**  
**12 Gorodesky Street**  
**Rehovot(IL)**  
Inventor: **Lebens, Michael Richard**  
**19A Hehalutz Street**  
**Jerusalem(IL)**  
Inventor: **Chaleff, Deborah Tardy**  
**31 Arvida Drive**  
**Pennington, Mercer, New Jersey 08534(US)**

(74) Representative: **Wächtershäuser, Günter, Dr.**  
**Tal 29**  
**W-8000 München 2(DE)**

(54) **Somatotropins with alterations in the alpha-helix 1 region, and combinations with other mutations.**

(57) The present invention relates to somatotropin analogues with amino acid changes in the alpha-helix 1 regions of said somatotropins, alone or in combination with mutations in the alpha-helix 3 and/or alpha-helix 2 regions, plus combinations with other changes to the native amino acid sequence of somatotropins. The resulting analogues are stable for formulation in sustained release formulations, while maintaining biological activity. Further, methods for conducting site-directed mutagenesis on DNA encoding proteins and/or polypeptide also are provided.

**EP 0 496 973 A2**

**BID**

## BACKGROUND OF THE INVENTION

The present invention relates to somatotropin analogues with amino acid changes in the alpha-helix 1, alone or in combination with mutations with the alpha-helix 3 and/or alpha-helix 2 portion of said somatotropins and to methods for producing the changes in the alpha-helix 1, as well as other regions, of recombinantly-produced polypeptides or proteins. Administration of exogenous somatotropins significantly increases the growth performance of a variety of animals, in particular livestock animals such as swine, but also fish species, as well. This growth enhancement in livestock in particular is usually characterized by an increase in muscle mass accretion concomitant with a decrease in fat, resulting in larger, leaner animals. The feed efficiency of animals receiving exogenous somatotropin also is significantly improved, resulting from an increase in weight gain and a concomitant decrease in feed consumption.

Exogenous administration of somatotropin is achieved in several ways, such as daily injections. In certain instances, however, other routes of administration may be preferred. For instance, an implanted device which allows sustained release of somatotropin over a defined time period may be helpful when treating certain livestock. A more desired route of administration is via an implanted device that allows sustained release over a defined period of time. Such a device would contain large amounts of somatotropin in very high concentrations (ca 500 mg/ml). Further, a somatotropin molecule having high solubility and a low tendency to form insoluble, biologically inactive aggregates is required for such delivery uses.

Somatotropins contain four  $\alpha$ -helices which assemble to form an  $\alpha$ -helical bundle (Abdel-Meguid et al, 1987). Typically, amino acid side chains projecting into the core of this structure are non-polar, hydrophobic and very tightly packed together in order to exclude penetration of a polar solvent (such as water or saline) into the center of the bundle. In the case of bovine somatotropin, which is related to porcine somatotropin in primary sequence, exposure of the hydrophobic face of  $\alpha$ -helix 3 (from amino acid residues tyr<sup>103</sup> to leu<sup>127</sup>) under protein concentrations in excess of 1 mg/ml promotes the formation of "associative intermediates", which are hypothesized to be a nucleating event in aggregate formation (Brems et al, 1986; Brems, 1988). These associative intermediates may represent alternate packing arrangements of this  $\alpha$ -helix from several individual somatotropin molecules, resulting in a multimeric structure in which the hydrophobic faces of this helix are resequestered from the aqueous environment. Formation of the associative intermediates can be blocked by addition of an excess of a protein fragment-containing  $\alpha$ -helix 3 (Brems, et al, 1986). In addition, extending the hydrophobic face of this helix, by replacing lysine at position 112 with leucine, greatly exacerbates the tendency to form associative intermediates (Brems, 1988).

The present invention addresses the problem of low solubility of somatotropins by altering the  $\alpha$ -helix 3 regions of the somatotropins. Specifically, porcine somatotropins with enhanced solution stability in vitro are made by site-directed mutagenesis of  $\alpha$ -helix 3. Both the hydrophobic and hydrophilic faces are targeted for mutagenesis. Recently site-directed mutations in the  $\alpha$ -helix 3 region of bovine somatotropin resulted in suppressed growth of transgenic mice expressing the mutant somatotropin, a result suggesting that the  $\alpha$ -helix 3 region is a region important for which biological activity may be maintained (Chen et al, 1990).

In addition,  $\alpha$ -helix 3 mutations are combined, where appropriate, with mutations in the helix 1 or helix 2 regions, and with double mutations in the DNA encoding cysteine at positions 183 and 191, where DNA encoding cysteine is replaced with either alanine or glutamic acid encoding DNA. The double mutations at positions 183 and 191 are described in EP355460, incorporated herein by reference thereto. Through the use of the mutations disclosed herein, somatotropins with enhanced solubility (stability), and thereby enhanced properties for sustained release, are provided. Porcine somatotropin is particularly useful in a sustained release form, and as such is a somatotropin of primary interest.

A particularly useful example of the present mutation is mutation I122L, in which the isoleucine at position 122 in  $\alpha$ -helix 3 is replaced with leucine. In combination with other mutations at positions 183 and 191 where the cysteines are replaced by alanine, a significant increase in the transition temperature of the protein's single tryptophan residue is obtained. The transition temperature is a measure of the thermal stability of the protein. In one of the most preferred mutation, enhanced solution stability is obtained when the I122L mutation is combined with mutations in which the cysteine-encoding DNA at positions 183 and 191 are altered to encode glutamic acid. In another preferred mutation, enhanced solution stability is achieved when the helix I double mutant A6TS11R is combined with mutations in which the cysteine-encoding DNA at positions 183 and 191 in the amino acid sequence are altered to encode glutamic acid.

## BRIEF DESCRIPTION OF THE DRAWINGS

FIGURE 1: Restriction map of recombinant porcine somatotropin (rpST) DNA. The wide solid line represents the amino acid-encoding portion of rpST DNA; the slender line represents the

5' and 3' flanking, non-coding DNA sequence. Regions of rpST gene subject to site directed mutagenesis are numbered and indicated below the restriction map, in which number 1 represents DNA encoding  $\alpha$ -helix 1, number 2 represents DNA encoding  $\alpha$ -helix 2, number 3 represents DNA encoding  $\alpha$ -helix 3 and number 4 represents the DNA encoding the cysteines present at positions 183 and 191. The letters above the map denote the location of various restriction endonuclease restriction sites, in which RI = EcoRI, N = NdeI, B = BssHII, S = SacI, X = XbaI, Sm = SmaI and H = HindIII.

FIGURE 2: Structure and restriction map of plasmid pEFF-902. This plasmid contains the pBR322 replication origin (Ori) and ampicillin resistance gene, the  $\lambda P_L$  promoter, the cII ribosome binding site and cI repressor gene from bacteriophage  $\lambda$ , the  $T_1 T_2$  transcription terminator from the *E. coli* *rrnB* operon, a 60-base pair sequence from the *deo* regulatory region without promoters, and the rpST gene denoted as pGH. Relevant restriction sites are indicated. The rpST-containing DNA is excised from this plasmid by treatment with EcoRI and HindIII and cloned into mutagenesis vector pGEM3z(f+) as described in the text.

FIGURE 3: Structure and partial restriction map of pGHGEM3Z. This phagemid contains the f1 DNA replication origin, the pBR322 replication origin (Ori) and ampicillin resistance gene, the SP6 and T7 promoters, the lacZ gene cII ribosome binding site from bacteriophage  $\lambda$  and the rpST gene, denoted rpGH. Single stranded phagemid DNA is used as the template for site directed mutagenesis as described in the text.

FIGURE 4: Bacterial expression plasmid pROpST is used for production of recombinant porcine somatotropins in bacteria (*E. coli*). The cII ribosome binding site is located between the EcoRI and NdeI restriction sites. The translational initiation codon for rpST is embedded in the NdeI site. Expression is driven by the  $\lambda P_L$  promoter.

FIGURE 5: Structure of yeast expression plasmid YEp352-pST-I122L. This plasmid is a derivative of YEp352 and contains the rpST mutation, I122L, whose expression is driven by the inducible GAL1 GAL10 promoter from *S. cerevisiae*. The 3' untranslated DNA is derived from the yeast STE7 gene. The 2  $\mu$ m element supports plasmid replication in yeast, and the URA3 provides a selectable marker for the transformant selection in yeast. This plasmid also carries the pBR322 origin of replication (not shown) and the ampicillin resistance gene.

## SUMMARY OF THE INVENTION

The present invention relates to somatotropin(s) with amino acid sequence changes in the  $\alpha$ -helix 1 regions, either alone or in combination with mutations in the  $\alpha$ -helix 3 and/or  $\alpha$ -helix 2 regions of the somatotropin molecule. Further, other mutations in the somatotropin molecule may be combined with the present helix mutations. The resulting somatotropin is more stable (soluble) than the native form of the somatotropin and maintains biological activity when formulated as a sustained release formulation of said somatotropin. More specifically, the somatotropins of the present invention include human, bovine, porcine, ovine, caprine, equine, fish and avian somatotropins. Further, the term somatotropin encompasses deletions, additions and alterations to other portions of the native somatotropin molecule. For instance, modified (substituted or eliminated cysteines) or derivatized somatotropins in which one to four of the cysteine amino acid residues of said somatotropin are replaced by from one to four amino acid residues, separately selected from the amino acids, arginine, lysine, aspartic acid, glutamic acid, asparagine, glutamine, histidine, alanine, glycine, isoleucine, leucine, valine, phenylalanine, tryptophan, tyrosine, methionine, serine, threonine or proline; or in which all four cysteines are converted to cysteic acid.

It is an object of the present invention, therefore, to provide novel somatotropins which are more soluble than the native form of the molecule and are thus biologically effective when formulated, preferably in sustained release formulations. It is a further object of the present invention to provide site-directed mutagenesis techniques for making the somatotropins of the present invention, as well as other recombinantly-produced polypeptides and/or proteins. These and further objects of the invention will be apparent by the following detailed description of the invention.

The plasmids, DNA sequences and microorganisms deposited in connection with the present patent application, except where specified to the contrary, are deposited in American Cyanamid Company's culture collection maintained in Princeton, New Jersey and are deposited pursuant to the Budapest Treaty with the American Type Culture Collection (ATCC) in Rockville, Maryland 20952, U.S.A.

The DNA strains referred to hereinabove were deposited in the ATCC on August 23, 1988. They are pGEMpST-SX (ATCC number 40482), pRO211 (ATCC number 40483) and pEFF-902 (ATCC number

40484). It is recognized by those skilled in the art that these DNAs can be inserted into any appropriate expression system to obtain the somatotropins of the invention or mutations thereof.

The *E. coli* K12 bacterial strains expressing some of the novel animal somatotropins of the present invention also were deposited in the ATCC on August 23, 1988. The bacterial strains include *E. coli* strain 1655 (ATCC number 67762), 1655/pROpSTA34 (ATCC number 67763), 1655/pROpSTE34 (ATCC number 67764), 1655/pROpST (ATCC number 67765), 4200 (ATCC number 67766), 4200/pROpSTA34 (ATCC number 67767), 4200/pROpSTE34 (ATCC number 67768), 4200/pROpST (ATCC number 67769), 4255 (ATCC number 67770), 4255/pROpSTA34 (ATCC number 67771), 4255/pROpSTE34 (ATCC number 67772), 4255/pROpST (ATCC number 67773) and 4300 (ATCC number 67774).

The following *E. coli* K12 bacterial strains also were deposited in the ATCC on September 21, 1990. These include pROpST-SXE-Q21HH22R (ATCC 68410), pROpST-SXE-G121A (ATCC 68411), pROpST-SXE-A6TS11R (ATCC 68412), pROpST-SXA-S81, 87L + I122L (ATCC 68413), pROpST-SXA-S81,87L (ATCC 68414), pROpST-SXA-L82, 84Q + L115K (ATCC 68415), pROpST-SXA-L82, 84Q (ATCC 68416), pROpST-SXE-I122L (ATCC 68417), pROpST-SXA-I122L (ATCC 68418), pST-SX (ATCC 68419), pROpST-SXA-L118E (ATCC 68420), pROpST-SXA-E119LQ123L (ATCC 68421), pROpST-SXA-I122E (ATCC 68422), pROpST-SXA-M126A (ATCC 68423) and pROpST-SXE-A6TS11R + I122L (ATCC 68424).

#### DETAILED DESCRIPTION OF THE INVENTION

The animal somatotropins of the present invention are provided by site directed mutagenesis, but other means such as chemically synthesizing the peptides and/or proteins may be employed in producing said somatotropins. Currently-utilized techniques for the alteration of the DNA sequence of a cloned segment of DNA at a specific defined site require the production of a single stranded form of that DNA. The single stranded DNA is annealed to a synthetic oligonucleotide which is complementary to a portion of that DNA except that the oligonucleotide contains within it a region of mismatch. The region of mismatch is usually located in the central portion of the oligonucleotide. In some instances, the oligonucleotide also contains a restriction endonuclease recognition site at or near the site of the mutation(s). The annealed mixture is then made double stranded and covalently closed by the addition of *E. coli* DNA polymerase I, large fragment and deoxynucleotide triphosphates in the presence of T4 DNA ligase and adenosine 5' triphosphate. The double stranded DNA is then transformed into an appropriate *E. coli* strain where the mismatched region of the DNA is repaired and replicated.

Two populations of clones are obtained. Depending on which strand is chosen as the template for repair synthesis, a clone either contains the wild type or the altered (mutated) sequence. The clones which contain the mutated sequence, that which corresponds to the sequence of the oligonucleotide, are selected by hybridization to the radioactively-labelled oligonucleotide. Due to mismatch between the oligonucleotide and the wild type sequence, the radioactively-labelled oligonucleotide is more stably bound to the clones which contain the mutated sequence. Incubation at an appropriate temperature therefore discriminates between wild type and mutated clones. In cases in which the oligonucleotide also contains a restriction endonuclease cleavage site, digestion of candidate clones with the cognate restriction endonuclease reveals clones which contain the mutated sequence and provides another means of discriminating between wild type and mutated clones. The alterations in the identified clones then are confirmed by DNA sequencing of the relevant regions.

Restriction fragments of plasmid clones containing the desired mutation(s) are reconstructed into expression plasmids suitable for expressing the mutant gene product in either bacteria or yeast, but not both. This reconstruction is achieved by standard subcloning procedures.

In the following discussions, recombinant porcine somatotropin is selected as representative of the modified recombinant somatotropins of the present invention and the methods employed for their preparation. Further, the following description and examples are illustrative of the present invention and not limited thereof.

The DNA and amino acid sequence of recombinant porcine somatotropin is provided hereinbelow. The most preferred recombinant porcine somatotropin is a polypeptide sequence of 193 amino acids, in which the NH<sub>2</sub>-terminus has been modified to include 3 additional amino acids (met, asp, gln) and a deletion of the first amino acid (ala) found in some mature forms of pituitary-derived porcine somatotropin. However the 191 amino acids PST as well as other derivatives thereof, such as deletions at the NH<sub>2</sub>-terminus, additions thereof, and/or deletions and/or additions at the COOH-terminus are meant to form part of the present invention.

Recombinant pST: NH<sub>2</sub>-met-asp-gln-phe-pro-ala-185 amino acids-ala-phe-COOH  
Pituitary pST: NH<sub>2</sub>-ala-phe-pro-ala-185 amino acids-ala-phe-COOH

## EP 0 496 973 A2

This modification results in a net increase of two additional amino acids in the recombinant pST protein and is described in EP355460. The numbering system employed in the description of the mutagenized derivatives of recombinant porcine somatotropin reflects this additional increase, and is easily applied by any practitioner skilled in the art.

5

10

15

20

25

30

35

40

45

50

55

## Recombinant Porcine Somatotropin

5	ATG GAT CAA TTC CCA GCC ATG CCC TTG TCC AGC CTA TTT GCC AAC	45
	Met Asp Gln Phe Pro Ala Met Pro Leu Ser Ser Leu Phe Ala Asn	
	1 5 10 15	
10	GCC GTG CTC CGG GCC CAG CAC CTG CAC CAA CTG GCT GCC GAC ACC	90
	Ala Val Leu Arg Ala Gln His Leu His Gln Leu Ala Ala Asp Thr	
	20 25 30	
15	TAC AAG GAG TTT GAG CGC GCC TAC ATC CCG GAG GGA CAG AGG TAC	135
	Tyr Lys Glu Phe Glu Arg Ala Tyr Ile Pro Glu Gly Gln Arg Tyr	
	35 30 35	
20	TCC ATC CAG AAC GCC CAG GCT GCC TTC TGC TTC TCG GAG ACC ATC	180
	Ser Ile Gln Asn Ala Gln Ala Ala Phe Cys Phe Ser Glu Thr Ile	
	50 55 60	
25	CCG GCC CCC ACG GGC AAG GAC GAG GCC CAG CAG AGA TCG GAC GTG	225
	Pro Ala Pro Thr Gly Lys Asp Glu Ala Gln Gln Arg Ser Asp Val	
	65 70 75	
30	GAG CTG CTG CGC TTC TCG CTG CTG CTC ATC CAG TCG TGG CTC GGG	270
	Glu Leu Leu Arg Phe Ser Leu Leu Leu Ile Gln Ser Trp Leu Gly	
	80 85 90	
35	CCC GTG CAG TTC CTC AGC AGG GTC TTC ACC AAC AGC CTG GTG TTT	315
	Pro Val Gln Phe Leu Ser Arg Val Phe Thr Asn Ser Leu Val Phe	
	95 100 105	
40	GGC ACC TCA GAC CGC GTC TAC GAG AAG CTG AAG GAC CTG GAG GAG	360
	Gly Thr Ser Asp Arg Val Tyr Glu Lys Leu Lys Asp Leu Glu Glu	
	110 115 120	
45	GGC ATC CAG GCC CTG ATG CGG GAG CTG GAG GAT GGC AGC CCC CGG	405
	Gly Ile Gln Ala Leu Met Arg Glu Leu Glu Asp Gly Ser Pro Arg	
	125 130 135	
50	GCA GGA CAG ATC CTC AAG CAA ACC TAC GAC AAA TTT GAC ACA AAC	450
	Ala Gly Gln Ile Leu Lys Gln Thr Tyr Asp Lys Phe Asp Thr Asn	
	140 145 150	
55	TTG CGC AGT GAT GAC GCG CTG CTT AAG AAC TAC GGG CTG CTC TCC	495
	Leu Arg Ser Asp Asp Ala Leu Leu Lys Asn Tyr Gly Leu Leu Ser	
	155 160 165	
60	TGC TTC AAG AAG GAC CTG CAC AAG GCT GAG ACA TAC CTG CGG GTC	540
	Cys Phe Lys Lys Asp Leu His Lys Ala Glu Thr Tyr Leu Arg Val	
	170 175 180	
65	ATG AAG TGT CGC CGC TTC GTG GAG AGC AGC TGT GCC TTC	579
	Met Lys Cys Arg Arg Phe Val Glu Ser Ser Cys Ala Phe	
	180 190	

Construction of pGEMpST-SX DNA

5 Single stranded pGEMpST-SX DNA is the template DNA for all of the mutagenesis reactions and is prepared from pGHGEM3Z DNA by site directed mutagenesis. Cloning of the porcine somatotropin (rpST) gene into the phagemid pGEM-3z(+), resulting in pGHGEM3Z, is achieved by the following general procedure. A fragment of DNA containing the pGHGEM3Z porcine somatotropin (rpST) gene is isolated from the bacterial expression plasmid pEFF-902 by cleavage with the restriction enzymes EcoRI and HindIII (Figure 1). The rpST gene-containing fragment is then purified by agarose gel electrophoresis. Double stranded phagemid DNA pGEM-3z(+) is digested with EcoRI and HindIII, treated with calf intestinal EcoRI alkaline phosphatase and the large fragment purified by agarose gel electrophoresis. The two purified fragments are then mixed together and ligated with T4 DNA ligase. The mixture is transformed into bacteria and several resultant colonies grown. Plasmid DNA is prepared by a standard alkaline lysis method and the structure determined by digestion with appropriate restriction enzymes. A clone is isolated which contains the expected fragments and is designated pGHGEM3Z.

nGEMpST-SX

20 The aim of this mutagenesis is to create an rpST DNA sequence in which the DNA sequence encoding  $\alpha$ -helix 2 is bounded on the 5' side (from positions 225-230 of the DNA coding region) by a SacI restriction site and the 3' side (from positions 285-290) by an XbaI restriction site. These alterations in the DNA sequence do not change the amino acid sequence of the rpST protein. The presence of these restriction endonuclease cleavage sites results in the creation of a "helix 2 cassette", so that mutations in the helix 2-encoding DNA can be conveniently and rapidly combined with appropriate mutations in the DNA encoding helix 3. The construction of pGEMpST-SX is described below.

The DNA sequences of synthetic oligonucleotides SacI293 and XbaI353 are described in Table 1. Single stranded pGHGEM3Z DNA is the substrate for mutagenesis and is prepared from purified phage by standard protocols. 2000 ng of this DNA is mixed with 100 ng each of the SacI293 and XbaI353 oligonucleotide, both of which have been phosphorylated at their 5' ends with adenosine 5' triphosphate and T4 polynucleotide kinase. The mixture is contained in a total volume of 10  $\mu$ L in IX annealing buffer (IX annealing buffer is 75 mM KCl and 5 mM Tris-Cl, pH 8.0). The mixture is heated at 65°C for 7 minutes followed by a 10 minute incubation at room temperature (RT). This procedure permits the oligonucleotides to anneal to the single stranded substrate (template) DNA. Annealed molecules are extended and converted to covalently closed, double stranded DNA by the addition of 22  $\mu$ L H<sub>2</sub>O, 1  $\mu$ L 20 mM ATP, 2 units each of T4 DNA ligase, and DNA polymerase I large fragment (for unit definition, see New England Biolabs catalogue, 1989), 2  $\mu$ L 20X dNTP's (a mixture of the four deoxyribonucleotide 5' triphosphates each at a concentration of 2 mM) and 4  $\mu$ L 10X "fill in" buffer (1X fill in buffer is 27.5 mM Tris-Cl, pH 7.5, 15 mM MgCl<sub>2</sub>, 2 mM DTT). After a one hour incubation at room temperature (RT), half of the reaction is introduced into HB101 competent cells by a standard protocol. Single colonies are apparent after overnight incubation at 37°C. Plasmid DNA is prepared by a standard procedure from 24 colonies, and digested, in separate reactions, with SacI and XbaI. Plasmid DNA's containing both restriction sites, which indicated the incorporation of both the SacI293 and XbaI353 oligonucleotides into the rpST gene, are further purified by introduction into HB101 competent cells as described previously. Plasmid DNA is prepared and digested in separate reactions with SacI and XbaI to verify the presence of each restriction site in the plasmid DNA, which is then confirmed by DNA sequence analysis of the relevant regions of the rpST DNA.

50

55

TABLE I

MUTAGENIC OLIGONUCLEOTIDES

	Name	Sequence (5'-3')	Mutation
5	SacI293	GACGTGGAGCTCCTGCGCTTCTCG	Helix 2 cassette
	XbaI353	CAGTTCTCTCTAGAGTCTTCACC	Helix 2 cassette
	S81L	TGCGCTTCTTGTGCTGCTGC	S81,87L
	S87L	TCATCCAGTTGTGGCTCG	S81,87L
10	Q8082	TGCGCTTCTCGCAGCTGCAGAT	L82,84Q
		CCAGTCGTGG	
	Q8082D	TTCTCGCAGCTGCAGATCCAGT	L82,84Q detection probe
	K113	CTACGAGAAGAAGAAGGACCTG	L115K
15	E116	GCTGAAGGACGAGGAGGAGGGC	L118E
	K113E116	GTCTACGAGAAGAAGAAGGACG	L115KL118E
		AGGAGGAGGGCAT	
	K113E116D	AGAAGAAGAAGGACGAGGAGGA	K113E116 Probe
20	E116K120	AAGCTGAAGGACGAGGAGGAGG	L118E1122K
		GCAAGCAGGCCCTGATG	
	E120	GGAGGAGGGCGAGCAGGCCCTG	I122E
	L120-3	GGAGGAGGGCCTGCAGGCCCTG	I122L
	A124-2	CAGGCCCTGGCAGGGAGCTGG	M126A
25	E113EHQ116	CGCGTCTACGAGAAGGAGAAGGAC(GC)	L115E
		A(GC)GAGGAGGGCATCCAG	
	E113D	CGTCTACGAGAAGGAGAAGGAC	L115E construction probe
	L115A	CTACGAGAAGGCCGAAGGACCTG	
	L118A	GCTGAAGGACGCGGAGGAGGGC	
30	L118TK	CTGAAGGACA(CA)AGAGGAGGGCAT	L118K
	L118T	CTGAAGGACACTGAGGAGGGC	L118T
	L117,121	GAAGGACCTGCTGGAGGGCAT	E119LQ123L
		CCTGGCCCTGATG	
	Leu117121D	CCTGCTGGAGGGCATCCTGGCC	E119LQ123L probe
35	K114R/AccI	GACCGCGTATACGAGCGTCTGAAGGA	K114R
	G121A/XmnI	CTGGAGGAAGCTATTCAGGCCCTG	G121A
	K116R/BglII	AGAAGCTGCGAGATCTGGAGGA	K116R
	A14D/HindIII	CCTTGTCAGCTTATTTGACAACGCCG	A14D
40	A6T	TCAATTCCCAACCATGC	A6T
	S11RA14D/Sal	ATGCCCTTGAGTCGACTAT	
		TTGACAACGCC	S11RA14D
	Q21HH22R/ClaI	CCGGGCCCATCGAATGCACCAA	Q21HH22R
45	PvuII634	AGAAGGCAGAGCTGCTGTCCAC	I122L PCR

Synthesis of Mutations in Helices 1, 2, or 3

50

Mutagenesis of the rpST gene in pGEMpST-SX is achieved as described below. The aim of the mutagenesis program is to generate an rpsT molecule that has a decreased tendency to aggregate at high protein concentrations (>100 mg/ml). The focus is the hydrophobic face of helix 3, from amino acid residues 112 through 129, which is believed to be critical in the initiation of an aggregation reaction (Brems et al., 1986). Because the rpST gene employed here encodes an additional 2 amino acids at the amino-terminus, the total number of amino acid residues is 193, as opposed to the 191 residues found in pituitary-derived bovine and porcine somatotropin. Residues 112 through 129 correspond to residues 110 through 127 of bovine somatotropin (Abdel-Meguid et. al., 1987). Other regions of the molecule that are targeted for



mutagenesis are helix 2, from residues 81 through 87, the hydrophilic face of helix 3 and helix 1 from residues 6 through 11. Combination mutants are generated by additional rounds of mutagenesis, or by subcloning relevant regions. The basic protocol used to obtain the L118E mutation and examples of all others are hereinafter described. Variations in the basic protocol are described in the appropriate examples.

5 Preparation of single stranded substrate pGEMpST-SX DNA is precisely as described for pGHGEM3Z. The DNA sequence of the synthetic mutagenic oligonucleotide used in the construction of mutation L118E, E116, is displayed in Table I and is phosphorylated at its 5' end as described for SacI293. The annealing and fill in reactions are also exactly as described for SacI293 mutagenesis of pGHGEM3Z. After introduction of half of the reaction mix into HB101 competent cells and overnight incubation at 37°C, the resultant colonies  
10 are transferred to nitrocellulose filters and processed for hybridization by standard methods. The E116 oligonucleotide is also used for detection of the mutation. It is radioactively labelled at the 5' end with  $\gamma$ -<sup>32</sup>P-ATP and polynucleotide kinase. Hybridization is overnight at 37°C in 5XSSC (1XSSC is 0.15 M sodium chloride, 0.015 M sodium citrate pH7.0), 1X Denhardt's (0.02% each (w/v) Ficoll, bovine serum albumin, polyvinylpyrrolidone), 150 µg/ml yeast tRNA and the radio-labelled probe.

15 After hybridization, the filters are washed for at least 30 minutes at 37°C in 5XSSC, followed by two thirty minute washes in TAC (TAC is 3M tetramethyl ammonium chloride, 50mM (tris) [hydromethyl] aminomethane pH 8.0, 1 mM EDTA (ethylenediamine tetraacetic acid), 0.1% (w/v) sodium dodecyl sulfate) at the desired temperature. The incubation temperature of this latter wash determines the specificity, as the E116 oligonucleotide will remain hybridized only to completely complementary clones. For the E116  
20 oligonucleotide, the temperature is 59.0°C. After exposure to X-Ray film, only those clones which are completely complementary to E116 are observed. Plasmid DNA is prepared from several of these positive scoring colonies, reintroduced into HB101 and screened as described hereinabove. Plasmid DNA from several positives from this second round of screening is prepared and analyzed by DNA sequence analysis; those containing the L118E mutation are thus unambiguously identified. The plasmid bearing this mutation  
25 is designated pGEMpST-SX-L118E.

The resultant rpST gene clones containing the L118E mutation are transferred into each of two expression vectors, pROpST-SX and pROpST-SXA, whose constructions are described. The object of these constructions is to introduce the rpST gene containing the helix 2 cassette, defined by the presence of the SacI and XbaI restriction sites previously described, into a plasmid vector designed for expression of the  
30 rpST gene in *E. coli*. An additional objective is to introduce the mutations described in the present invention into each of two different rpST genetic backgrounds. One is natural (wild type) with respect to the presence of each of two cysteine residues at positions 183 and 191. The other rpsT gene encodes alanine instead of cysteine at these same positions and is described in EPO 355460. Plasmid pROpSTA34 (Figure 4) contains an EcoRI/HindIII fragment cloned into expression plasmid pRO211. This EcoRI/HindIII fragment carries an  
35 altered rpST gene, in which the DNA encoding the cysteines at positions 103 and 191 has been mutated to alanine-encoding DNA in these positions. It thus carries the ala, ala mutations. Plasmid pROpSTA34 is digested with EcoRI and HindIII in one reaction mixture and EcoRI and SmaI in another. The large, vector-containing fragment is purified from each reaction by agarose gel electrophoresis. Plasmid pROpST-SX, which contains the helix 2 cassette in the otherwise wild type rpsT background, is generated by ligation of  
40 the purified EcoRI/HindIII fragment from pGEMpST-SX. The ligation mixture is introduced into bacterial strain N99cl. In this strain, rpST expression is driven by the  $\lambda$  PL promoter, is prevented by the presence of the wild type  $\lambda$  repressor. Resultant plasmid clones with the desired construction are identified by digestion with the appropriate restriction enzymes. Plasmid pROpST-SXA, which contains the helix 2 cassette in the mutated rpST gene, is generated from ligation of the purified EcoRI/SmaI vector fragment from pROpSTA34  
45 with the purified EcoRI/SmaI fragment from pGEMpST-SX. The ligation mixture is introduced into bacterial strain N99cl, and the resultant plasmid clones analyzed by digestion with the relevant restriction enzymes to identify the desired plasmid clones.

The L118E mutation is introduced into expression plasmids pROpST-SX and pROpST-SXA by cleaving pGEMpST-SX-L118E DNA with EcoRI and HindIII in one set of reactions, and EcoRI and SmaI in the other  
50 set of reactions. The small, rpsT-bearing fragments from each reaction mixture contain the L118E mutation and are purified by agarose gel electrophoresis. Plasmid pROpST-SX is restricted with EcoRI and Hind III, and the large vector-bearing fragment is purified by agarose gel electrophoresis. This fragment is ligated with the purified EcoRI/HindIII fragment from pGEMpST-SX-L118E, resulting in plasmid pROpST-SX-L118E. The ligation mix is transformed into expression strain 4300, which carries a temperature-sensitive  $\lambda$   
55 repressor. In these strains, rpST expression depends on temperature. At 42°C the  $\lambda$  repressor is inactive, permitting expression from the  $\lambda$ P<sub>L</sub> promoter. Bacterial colonies carrying the pROpST-SX-L118E plasmid are identified by their ability to produce the rpsT protein at 42°C (the non-permissive temperature for the  $\lambda$  repressor). Plasmid pROpST-SXA is restricted with both EcoRI and SmaI, and the large vector fragment is

purified by agarose gel electrophoresis. This fragment is ligated with the purified EcoRI/SmaI fragment from pGEMpST-SX-L118E, resulting in plasmid pROpST-SXA-L118E. The ligation mix is transformed into expression strain 4300, and bacterial colonies carrying the pROpST-SXA-L118E plasmid are identified by their ability to produce the rpST protein at 42°C.

#### EXAMPLE 1

##### CREATION OF A HELIX 2 "CASSETTE" USING TWO SYNTHETIC OLIGONUCLEOTIDES SIMULTANEOUSLY

The aim of this mutagenesis is to create an rpST DNA sequence in which the DNA sequence encoding  $\alpha$ -helix 2 is bounded on the 5' side (from positions 225-230 of the DNA coding region) by a SacI restriction site and the 3' side (from positions 285-290) by an XbaI restriction site. These alterations in the DNA sequence do not change the amino acid sequence of rpST. The presence of these restriction endonuclease cleavage sites results in the creation of a "helix 2 cassette", so that mutations in the helix 2-encoding DNA are conveniently and rapidly combined with appropriate mutations in the DNA encoding helix 3. The construction of pGEMpST-SX is as described hereinabove.

#### EXAMPLE 2

##### SUBSTITUTION OF HYDROPHOBIC AMINO ACIDS OF HELIX 3 WITH HYDROPHILIC AMINO ACIDS THAT STABILIZE $\alpha$ HELICES WITH MUTAGENIC OLIGONUCLEOTIDES

The members of this mutational class include mutations L118E, L115K, L115KL118E and L118EI122K. The mutations are generated precisely as described for L118E in the basic protocol. The resultant plasmids bearing these mutations are designated pGEMpST-SX-L118E, pGEMpST-SX-L115K, pGEMpST-SX-L115KL118E and pGEMpST-SX-L118EI122K, respectively.

The generation of the L115K mutation in rpST is achieved precisely as described for L118E, except that mutagenic oligonucleotide K113, displayed in Table I is used both in the mutagenesis and hybridization reactions. This oligonucleotide alters the rpST sequence so that the codon for leucine at position 115 is changed from CTG to AAG which encodes lysine.

The generation of the L115KL118E mutation in rpST is achieved precisely as described for L118E, except that mutagenic oligonucleotide K113E116 displayed in Table I is used in the mutagenesis reaction and oligonucleotide K113E116D, displayed in Table I is used in the hybridization reaction. The K113E116 oligonucleotide alters the rpST sequence so that the codon for leucine at position 115 is changed from CTG to AAG which encodes lysine, and the leucine codon at 118 is changed from CTG to GAG which encodes glutamic acid. This oligonucleotide thus creates a double mutation in the rpST DNA sequence.

The generation of the L118EI122K mutation in rpST is achieved precisely as described for L118E, except that mutagenic oligonucleotide E116I120 displayed in Table I, is used in the hybridization reactions. The E116K120 oligonucleotide alters the rpST sequence so that the codon for leucine at position 118 is changed from CTG to GAG which encodes glutamic acid, and the isoleucine codon at 120 is changed from ATC to AAG, which encodes lysine. This oligonucleotide thus creates a double mutation in the rpST DNA sequence.

#### EXAMPLE 3

##### SUBSTITUTION OF HYDROPHOBIC AMINO ACIDS IN HELIX 3 WITH HYDROPHILIC AMINO ACIDS WITH MUTAGENIC OLIGONUCLEOTIDES

The members of this mutational class include I122E, L118T, L118K and L115E. The plasmids bearing these mutations are designated pGEMpST-SX-I122E, pGEMpST-SX-L118T, pGEMpST-SX-L118K and pGEMpST-SX-L115E, respectively. The construction of these mutations is performed precisely as described for L118E except for the oligonucleotides used in both the mutagenesis and hybridization reactions, whose sequences are displayed in Table I.

Mutagenic oligonucleotide E120 is used in the construction of mutation I122E (Table I). This oligonucleotide alters the sequence of the rpST gene such that the codon for isoleucine at position 122 is converted from ATC to GAG which encodes glutamic acid. The E120 oligonucleotide is also used as the radio-labelled detection probe in the hybridization reactions, which in all other respects are identical to those

described above for L118E, except that the nitrocellulose filters are incubated in TAC buffer at 56°C. The construction of mutation L118T is performed precisely as described for L118E except that the oligonucleotide used in both the mutagenesis and hybridization reactions is L118T (Table I). This oligonucleotide alters the sequence of the rpST gene such that the codon for leucine at position 118 is converted from CTG to ACT which encodes threonine. Plasmids containing the desired mutation are distinguished from non-mutation bearing plasmids after the nitrocellulose filters are incubated in TAC buffer at 56°C.

The generation of the L115E mutation in rpST is achieved precisely as described for L118E, except that mutagenic oligonucleotide E113EHDQ116, displayed in Table I, is used in the mutagenesis reaction and oligonucleotide E113D, displayed in Table I, is used in the hybridization reactions. The E113EHDQ116 oligonucleotide alters the rpST sequence so that the codon for leucine at position 115 is changed from CTG to GAG which encodes glutamic acid, and the leucine codon at 118 is changed from CTG to GAG, which encodes glutamic acid, GAG, which encodes glutamic acid, GAC, which encodes aspartic acid, CAC, which encodes histidine or CAG, which encodes glutamine. The variety of mutational changes that occur at position 118 is due to the fact that the mutagenic oligonucleotide is a mixture of four oligonucleotides, generated during the synthesis of the oligonucleotide. DNA sequencing of the resultant plasmid clones that hybridize to the E113D radio-labelled hybridization probe reveal that they contain the L115E mutation, but none carry any of the four possible mutations at position 118. Thus, this mutagenesis results in only a single mutation at position 115.

The generation of the L118K mutation in rpST is achieved precisely as described for L118E, except that mutagenic oligonucleotide L118TK, whose sequence is displayed in Table I, is used. The L118TK oligonucleotide alters the rpST sequence so that the codon for leucine at position 118 is changed from CTG to AAG which encodes lysine or from CTG to CAG, which encodes threonine. The various possibilities for the mutational changes that arise at position 118 are due to the fact that the mutagenic oligonucleotide is a mixture of two oligonucleotides, generated during the synthesis of the oligonucleotide. DNA sequencing of the resultant plasmid clones that hybridize to the L118TK radio-labelled hybridization probe reveal that they contain the L115K mutation, and none carry the other possible mutations, L118T, at position 118. Thus, this mutagenesis results in a single mutation at position 118.

#### EXAMPLE 4

##### SUBSTITUTION OF HYDROPHILIC AMINO ACIDS IN HELIX 3 WITH HYDROPHOBIC AMINO ACIDS USING A MUTAGENIC OLIGONUCLEOTIDE

The single member of this mutational class is the double mutant, E119LQ123L. The plasmid bearing this mutation, confirmed by DNA sequence analysis, is pGEMpST-SX-E119LQ123L. The construction of this double mutant rpST gene is achieved as described for L118E except that mutagenic oligonucleotide L117,121 is used (Table I). This oligonucleotide alters the rpST DNA sequence such that the DNA encoding glutamic acid is changed from GAG to CTG, which encodes leucine, and the DNA encoding glutamine at position 123 is changed from CAG to CTG which encodes leucine. The mutagenesis reaction utilizes this oligonucleotide, while Leu117121D, whose sequence is displayed in Table I is used as the radio-labelled probe in the hybridization reactions. All of the procedures used in the construction of this mutation are as previously described for L118E, except that the nitrocellulose filters are incubated in TAC at 58°C to detect mutation-bearing plasmids.

#### EXAMPLE 5

##### SUBSTITUTION OF NON-POLAR AMINO ACIDS WITH LARGE SIDE CHAINS IN HELIX 3 WITH NON-POLAR AMINO ACIDS WITH SMALL SIDE CHAINS

The members of this mutational class include L115A, L118A and M126A. The plasmids bearing these mutations are designated pGEMpST-SX-L115A, pGEMpST-SX-L118A and pGEMpST-SX-M126A, respectively. The construction of these mutations is performed precisely as described for L118E except for the mutagenic oligonucleotides employed and, if necessary, the TAC wash temperature.

The DNA sequence of the synthetic mutagenic oligonucleotide used in the construction of mutation L115A, L115A, is displayed in Table I. This oligonucleotide alters the sequence of the rpST gene such that the codon for leucine at position 115 is converted from CTG to GCG which encodes alanine. The L115A oligonucleotide is also used as the radio-labelled detection probe in the hybridization reactions. Plasmids

containing the desired mutation are distinguished from non-mutation-bearing plasmids after nitrocellulose filters are incubated in TAC buffer at 56°C.

The generation of the L118A mutation in rpST is achieved precisely as described for L118E, except that the mutagenic oligonucleotide employed in both the mutagenesis and hybridization/screening reactions is L118A, whose sequence is displayed in Table I. The L118A oligonucleotide alters the rpST sequence so that the codon for leucine at position 118 is changed from CTG to GCG which encodes alanine. Mutation-bearing plasmids are detected by incubating the nitrocellulose in TAC buffer at 56°C. The plasmid bearing this mutation, confirmed by DNA sequence analysis, is designated pGEMpST-SX-L118A.

The generation of the M126A mutation in rpST is achieved precisely as described for L118E, except that the mutagenic oligonucleotide employed in both the mutagenesis and hybridization/screening reactions is A124-2, whose sequence is displayed in Table I. The A124-2 oligonucleotide alters the rpST sequence so that the codon for methionine at position 126 is changed from ATG to GCA which encodes alanine. Mutation-bearing plasmids are detected by incubating the nitrocellulose filters in TAC buffer at 56°C. The plasmid bearing this mutation, confirmed by DNA sequence analysis, is designated pGEMpST-SX-M126A.

#### EXAMPLE 6

##### SUBSTITUTION OF ISOLEUCINE 122 WITH LEUCINE

The members of this mutational class include I122L, I122LL118A and I122LM126A. The plasmids bearing these mutations are designated pGEMpST-SX-I122L, pGEMpST-SX-I122LL118A and pGEMpST-SX-I122LM126A, respectively. The construction of these mutations is performed precisely as described for L118E except for the mutagenic oligonucleotides employed and, if necessary, the TAC wash temperature.

The DNA sequence of the synthetic mutagenic oligonucleotide used in the construction of mutation I122L, L120-3, is displayed in Table I. This oligonucleotide alters the sequence of the rpST gene such that the codon for isoleucine at position 122 is converted from ATC to CTG which encodes leucine. The L120-3 oligonucleotide is also used as the radio-labelled detection probe in the hybridization reactions. Plasmids containing the desired mutation are distinguished from non-mutation-bearing plasmids after nitrocellulose filters are incubated in TAC buffer at 56°C.

The generation of the I122LL118A mutation in rpST is achieved precisely as described for L118E, except that the mutagenic oligonucleotide employed in both the mutagenesis and hybridization/screening reactions is L118A, and the template DNA used for mutagenesis is pGEMpST-SX-I122L. The template DNA is prepared precisely as described for pGEMpST-SX DNA. Mutation-bearing plasmids are detected by incubating the nitrocellulose filters in TAC buffer at 56°C. The plasmid bearing this mutation, confirmed by DNA sequence analysis, is designated pGEMpST-SX-L118AI122L. The generation of the I122LM126A mutation in rpST is achieved precisely as described for L118E, except that the mutagenic oligonucleotide employed in both the mutagenesis and hybridization/screening reactions is A124-2, and the template DNA used for mutagenesis is pGEMpST-SX-I122L. The template DNA is prepared precisely as described for pGEMpST-SX DNA. Mutation-bearing plasmids are detected by incubating the nitrocellulose filters in TAC buffer at 56°C. The plasmid bearing this mutation, confirmed by DNA sequence analysis, is designated pGEMpST-SX-I122LM126A.

#### EXAMPLE 7

##### SUBSTITUTION OF AMINO ACID RESIDUES ON THE HYDROPHILIC SURFACE OF HELIX 3

The members of this mutational class include G121A, K114R, and K116R. The plasmids bearing these mutations are designated pGEMpST-SX-G121A, pGEMpST-SX-K114R and pGEMpST-SX-K116R, respectively. The construction of these mutations is performed precisely as described for L118E except for the mutagenic oligonucleotides employed and, if necessary, the TAC wash temperature.

The DNA sequence of the synthetic mutagenic oligonucleotide useful in the construction of mutation G121A, G121A/XmnI is displayed in Table I. This oligonucleotide alters the sequence of the rpST gene such that the codon for glycine at position 121 is converted from GGC to GCT which encodes alanine. This oligonucleotide also differs from the rpST DNA sequence so that an XmnI restriction recognition site (5'-GAAGCTATTC-3') is incorporated into the rpST DNA sequence. Except for the G121A mutation, the additional nucleotide changes do not result in changes in the amino acid sequence of the rpST protein. The G121A/XmnI oligonucleotide is also used as the radio-labelled detection probe in the hybridization reactions, which in all other respects are identical to those described above. Candidate mutation-bearing clones are

detected by incubating the nitrocellulose filters in TAC buffer at 57.5°C and by assaying for the acquisition of an XmnI site, which is present in the mutagenic oligonucleotide and is therefore diagnostic of the presence of the G121A mutation in the plasmid clone. The plasmid bearing this mutation, confirmed by DNA sequence analysis, is designated pGEMpST-SX-G121A.

5 The generation of the K114R mutation in rpST is achieved precisely as described for L118E, except that the mutagenic oligonucleotide employed in both the mutagenesis and hybridization/screening reactions is K114R/AccI whose sequence is displayed in Table I. The K114R/AccI oligonucleotide alters the rpST sequence so that the codon for lysine at position 114 is changed from AAG to CGT which encodes arginine. This oligonucleotide also differs from the rpST DNA sequence such that an AccI restriction recognition site  
10 (5'-GTATAC-3') is incorporated into the rpST DNA sequence. Except for the K114R mutation, the additional nucleotide changes do not result in changes in the amino acid sequence of the rpST protein. Like G121A, putative mutation-bearing clones are detected by incubating the nitrocellulose filters in TAC buffer at 57.5°C and examined for acquisition of a new AccI restriction site which is present in the mutagenic oligonucleotide and is therefore diagnostic of the presence of the K114R mutation in the plasmid clone. The plasmid  
15 bearing this mutation, confirmed by DNA sequence analysis, is designated pGEMpST-SX-K114R.

The generation of the K116R mutation in rpST is achieved precisely as described for L118E, except that the mutagenic oligonucleotide employed in both the mutagenesis and hybridization/screening reactions is K116R/BglII whose sequence is displayed in Table 1. The K116R/BglII oligonucleotide alters the rpST sequence so that the codon for lysine at position 116 is changed from AAG to CGA which encodes arginine.  
20 This oligonucleotide also differs from the rpST DNA sequence so that a BglII restriction recognition site (5'-AGATCT-3') is incorporated into the rpST DNA sequence from positions 342-347 of the nucleotide sequence. Except for the K116R mutation, the additional nucleotide changes do not result in changes in the amino acid sequence of the rpST protein. Like G121A, putative mutation-bearing clones are detected by incubating the nitrocellulose filters in TAC at 57.5°C and examined for the acquisition of a new BglII  
25 restriction site which is present in the mutagenic oligonucleotide and is therefore diagnostic of the presence of the K116R mutation in the plasmid clone. The plasmid bearing this mutation, confirmed by DNA sequence analysis, is designated pGEMpST-SX-K116R.

#### EXAMPLE 8

#### 30 SUBSTITUTION OF HYDROPHILIC AMINO ACIDS IN HELIX 2 WITH HYDROPHOBIC AMINO ACID RESIDUES USING TWO SYNTHETIC OLIGONUCLEOTIDES SIMULTANEOUSLY

The member of this mutational class is the double mutation, S81,87L. The plasmid bearing this  
35 mutation, confirmed by DNA sequence analysis, is designated pGEMpST-SX-S81,87L. The DNA sequence of the synthetic mutagenic oligonucleotides, S81L and S87L, used in the construction of the double mutant S81,87L is given in Table I. The S81L and S87L oligonucleotides alter the sequence of the rpST gene such that the codon for serine at positions 81 and 87, respectively, are converted from TCG to TTG, which encodes leucine. The construction of this double mutant rpST gene is precisely as described for L118E  
40 except that both of the mutagenic oligonucleotides are used simultaneously in the mutagenesis reaction. The S81L oligonucleotide is also used as the radio-labelled detection probe in the hybridization reactions, which in all other respects are identical to those described for L118E, except that the filters are washed in TAC buffer at 54°C. Bacterial transformants carrying the putative positive mutation-bearing plasmid clones are selected, transferred to nitrocellulose filters and processed for hybridization. In this second round of  
45 screening, the S87L oligonucleotide is used as the radio-labelled probe; filters are washed in TAC buffer at 54°C.

#### EXAMPLE 9

#### 50 SUBSTITUTION OF HYDROPHOBIC AMINO ACID RESIDUES IN HELIX 2 WITH HYDROPHILIC AMINO ACID RESIDUES

The single member of this mutational class is the double mutation, L82,84Q. The plasmid bearing this  
55 mutation, confirmed by DNA sequence analysis, is designated pGEMpST-SX-L82,84Q. The DNA sequence of the synthetic mutagenic oligonucleotide used in the construction of mutation L82,84Q is Q8082 and is displayed in Table I. This oligonucleotide alters the sequence of the rpST gene such that the codons for leucine at positions 82 and 84 are each converted from CTG and CTC, respectively, to CAG, which encodes glutamine. Mutation-bearing plasmids are detected by incubating the nitrocellulose filters in TAC buffer at

58°C.

#### EXAMPLE 10

##### 5 CONSTRUCTION OF HELIX 2 AND HELIX 3 COMBINATION MUTATIONS

Several helix 3 mutations, I122L, M126A, and E119LQ123L, which either retain (I122L, M126A,) or increase (E119LQ123L) the hydrophobic character of the hydrophobic surface of helix 3 are combined with the hydrophobic helix 2 double mutation, S81,87L by the following subcloning reactions. Plasmid  
 10 pGEMpST-SX-S81,87L is restricted with XbaI and EcoRI. The small fragment is purified by agarose gel electrophoresis and contains the S81,87L mutation. Plasmid pROpST-SXA-I122L is also restricted sequentially with XbaI and EcoRI, and the large fragment similarly is purified. The large fragment carries the pROpST expression vector components and the pST mutations I122L and the cysteine to alanine substitutions at positions 183 and 191. This large fragment, and the small S81,87L fragment, are joined in  
 15 the presence of T4 DNA ligase and ATP. Half of the reaction mixture is introduced into expression strain 4300, made competent by treatment with CaCl<sub>2</sub>. Transformed cells are cultured overnight at 30°C. Plasmid-bearing cells are assayed for pST expression as described in Example 12: plasmid containing this helix 2:helix 3 combination is designated pROpST-SXA-S81,87L + I122L.

Combination mutations pROpST-SXA-S81, 87L + M126A and pROpST-SXA-S81,87L + E119LQ123L are  
 20 constructed precisely as described for pROpST-SXA-S81,87L + I122L, except that pROpST-SXA-M126A and pROpST-SXA-E119LQ123L are used as the source of the expression vector components and the helix 3 mutation(s) for generating pROpST-SXA-S81,87L + M126A and pROpST-SXA-E119LQ123L, respectively.

The helix 2 double mutation L82,84Q is combined with the helix 3 mutation L115K exactly as described for S81,87L + I122L except that the source of mutant helix 2 DNA is pGEMpST-SXA-82,84Q and the source  
 25 of the helix 3 mutation, L115K, is pROpST-SXA-L115K. The plasmid containing this combination is designated pROpST-SXA-L82,84Q + L115K.

#### EXAMPLE 11

##### 30 SUBSTITUTION OF HYDROPHOBIC AMINO ACIDS IN OR NEAR HELIX 1 WITH HYDROPHILIC AMINO ACIDS USING MUTAGENIC OLIGONUCLEOTIDES

The object of these mutations is to replace hydrophobic amino acid residues found in the NH<sub>2</sub>-terminal portion of rpST with hydrophilic amino acid residues that are present in the same relative position of human  
 35 growth hormone.

Members of this mutational class include the rpST double mutation Q21HH22R, double mutation S11RA14D and single mutations A6T and A14D. Plasmids bearing these mutations are confirmed by DNA sequence analysis and are designated pGEMpST-SX-Q21HH22R, pGEMpST-SX-S11RA14D, pGEMpST-SX-A6T and pGEMpST-SX-A14D, respectively. The construction of these mutations is performed precisely  
 40 as described for L118E except for the mutagenic oligonucleotides employed, the incubation temperature of nitrocellulose filters in TAC buffer, and an additional screen for positive, mutation bearing plasmids by digestion with an appropriate restriction endonuclease, if and where appropriate.

The DNA sequence of the synthetic mutagenic oligonucleotide used in the construction of the double mutation Q21HH22R, Q21HH22R/Clal, is displayed in Table I. This oligonucleotide alters the sequence of  
 45 the rpST gene such that the codon for glutamine at position 21 is converted from CAG to CAT which encodes histidine, and the histidine at position 22 is converted from CAC to CGA, which encodes arginine. Embedded in these mutations is a Clal restriction endonuclease cleavage site (5'-ATCGAT-3'), which is unique to the altered rpST gene. The Q21HH22R/Clal oligonucleotide is also used as the radio-labelled detection probe in the hybridization reactions, which in all other respects are identical to those previously  
 50 described. All of the procedures used in the construction of this mutation are as previously described for L118E, except that the filters are washed in TAC buffer at 56°C. Also, candidate mutation-bearing clones are assayed for the acquisition of a Clal site, which is present in the mutagenic oligonucleotide and is therefore diagnostic of the presence of the Q21HH22R double mutation in the plasmid clone.

The generation of the A6T mutation in rpST is achieved precisely as described for L118E, except that  
 55 the mutagenic oligonucleotide A6T, displayed in Table I is used in both the mutagenesis and hybridization reactions. The A6T oligonucleotide alters the rpST sequence so that the codon for alanine at position 6 is converted from GCC to ACC, which encodes threonine. Subsequent to hybridization, the bacterial-containing nitrocellulose filters are washed in TAC buffer at 52°C.

The generation of the S11RA14D double mutation is achieved precisely as described for L118E, except that mutagenic oligonucleotide S11RA14D/Sall is used in both the mutagenesis and hybridization reactions, and that the nitrocellulose filters are washed in and TAC buffer at 64°C. The S11RA14D/SaII oligonucleotide alters the rpST sequence such that the serine codon at position 11 is converted from AGC to CGA, which encodes arginine, and the alanine codon at position 14 is converted from GCC to GAC, which encodes aspartic acid. This oligonucleotide also differs from the rpST DNA sequence so that a SaII restriction recognition site (5'-GTCGAC-3') is incorporated into the rpST DNA sequence from positions 29-34 of the nucleotide sequence. Except for the S11R and A14D mutations, the additional nucleotide changes do not result in changes in the amino acid sequence of the rpST protein. Putative mutation-bearing clones are examined for the acquisition of a new SaII restriction site which is present in the mutagenic oligonucleotide and is therefore diagnostic of the presence of the S11RA14D double mutation in the plasmid clone.

The generation of the A14D single mutation is achieved precisely as described for L118E, except that mutagenic oligonucleotide A14D/HindIII is used in both the mutagenesis and hybridization reactions. The A14D/HindIII oligonucleotide alters the rpST sequence such that the alanine codon at position 14 is converted from GCC to GAC, which encodes aspartic acid. This oligonucleotide also differs from the rpST DNA sequence so that a HindIII restriction recognition site (5'-AAGCTT-3') is incorporated into the rpST DNA sequence from positions 30-35 of the nucleotide sequence. Except for the A14D mutation, the additional nucleotide changes do not result in changes in the amino acid sequence of the rpST protein. Putative mutation-bearing clones are detected by incubating the nitrocellulose filters in TAC buffer at 62°C and examined for the acquisition of a new HindIII restriction site which is present in the mutagenic oligonucleotide and is therefore diagnostic of the presence of the A14D mutation in the plasmid clone.

#### EXAMPLE 12

#### RECONSTRUCTION OF pST MUTATIONS INTO APPROPRIATE BACTERIAL EXPRESSION PLASMIDS

The altered (mutation-bearing) clones are reconstructed into derivatives of the bacterial expression plasmid pRO211 (described in EPO173280 patent application incorporated herein by reference thereto), designated pROpST, pROpSTA34 and pROpSTE34. Plasmid pROpST contains pST DNA cloned into expression vector pRO211 and contains cysteine-encoding DNA at positions 183 and 191; pROpSTA34 contains alanine-encoding DNA and pROpSTE34 contains glutamic acid-encoding DNA at these positions. The pGEMpST altered clones are digested with EcoRI and SmaI and the small pST mutation-bearing fragment isolated. pROpSTA34 DNA is similarly treated, and the large, vector-containing DNA fragment is isolated. These purified fragments are ligated together with T4 DNA ligase and transformed into an appropriate bacterial strain, e.g. 4300. This strain contains a temperature sensitive  $\lambda$  repressor so that expression from the  $\lambda P_L$  promoter is prevented at 30°C, but permitted at 42°C, at which temperature the repressor is inactivated. Introduction of altered pGEMpST DNA fragments into pROpSTE34 DNA is achieved precisely as described for pROpSTA34. Introduction of altered pGEMpST DNA fragments into pROpST is identical to that described for pROpSTA34, except that both pGEMpST and pROpSTA34 plasmids are digested with EcoRI and HindIII. Table II lists the bacterial expression plasmids into which the mutated pST genes are introduced. pST mutations A6T, S11RA14D and Q21HH22R are introduced into a derivative of pROpSTE34 as described for pROpSTE34. This derivative, pROpSTE34T<sub>1</sub>T<sub>2</sub>, contains a ca. 1 kb HindIII fragment at the 3' end of the pST coding DNA, which contains the transcription terminator T<sub>1</sub>T<sub>2</sub> from the *E. coli* rrnB operon (the ribosomal RNA B operon).

TABLE II

EXPRESSION VECTOR CONSTRUCTIONS:AMINO ACID CONSTITUTION  
AT POSITIONS 183 AND 191

Mutation	Amino acid encoded at 183 and 191		
	cysteine	alanine	glutamic acid
I122L	+	+	+
L115K	+	+	+
L118E	+	+	
L115KL118E	+	+	
L118EI122K	+	+	
L115E		+	
I122E	+	+	
L118T		+	
L118K		+	
E119LQ123L	+	+	
L115A	+	+	
L118A	+	+	
M126A	+	+	
L118AI122L		+	
I122LM126A	+	+	+
S81,87L		+	
L82,84Q		+	
S81,87L+E119LQ123L		+	
" + I122L		+	
" + M126A		+	
L82,84Q+L115K		+	
A14D			
A6T			++
S11RA14D			++
Q21HH22R			++
A6TS11R			++
A6TS11R+I122L			+
P8TS11R+I122L			+
P8TS11R			+

\*Also contains the  $T_1T_2$  transcription terminator sequence from the E. coli *frnB* operon.

## EXAMPLE 13

CONSTRUCTION OF HELIX 1 COMBINATION MUTANTS A6TS11R + E34 AND P8TS11R + E34

Double mutation A6TS11R, in which the alanine at position 6 is replaced with threonine and serine at position 11 is replaced with arginine, is combined with the E34 mutations (described in EP355460), in which the DNA encoding cysteine at positions 183 and 191 are replaced with glutamic acid. The resultant rpST gene therefore contains mutations in both the  $NH_2$ - (A6TS11R) and  $COOH$ -encoding regions (E34) of the rpST DNA. The resulting plasmid is designated pROpSTE-A6TS11R. The altered, small, rpST-containing EcoRI/SmaI fragment from pML/pGH14, which contains the A6TS11R mutations, is joined to the large EcoRI/SmaI fragment from plasmid pROpSTE- $T_1T_2$ . This latter plasmid is the pST expression plasmid, which also contains the strong transcription terminator from the E. coli *rrnB* operon ( $T_1T_2$ ) at the 3' end of the rpST-encoding DNA.

Another double mutation, P8TS11R, in which the proline-encoding DNA at position 8 is mutated to



encode threonine, and the serine-encoding DNA is mutated to encode arginine is combined with the E34 mutations (described in EP355460), in which the DNA encoding cysteine at positions 183 and 191 are replaced with glutamic acid. The resultant rpST gene therefore contains mutations in both the NH<sub>2</sub>-(P8TS11R) and COOH-encoding regions (E34) of the rpST DNA. The resulting plasmid is designated pROpSTE-P8TS11R. The same strategy is employed in the construction of pROpSTE-P8TS11R as in pROpSTE-A6TS11R, except that plasmid pML:pGH18, which contains the P8TS11R double mutation is used as the source of the altered rpST DNA.

#### A6TS11R&I122L + E34 and P8TS11R + I112L + E34

The I112L helix 3 mutation described above is combined with each of the two helix 1 mutations, A6TS11R and P8TS11R and the E34 mutations. The resulting plasmids are designated pROpST-SXE-A6TS11R+I122L and pML:pGH18-SXE-I122L, respectively. pROpST-SXE-A6TS11R+I122L is constructed by joining the small I122L-containing BssHII/HindIII fragment with the large BssHII/HindIII fragment purified from pROpSTE-A6TS11R. This resulting plasmid contains the helix 2 cassette, defined by the SacI and XbaI restriction sites that flank the 5' and 3' ends of helix 2-encoding DNA previously described but does not contain the T<sub>1</sub>T<sub>2</sub> transcription terminator. Plasmid pML:pGH18-SXE-I122L is constructed in an identical fashion except that plasmid pML:pGH18 is used as the source of the large fragment, carrying the P8TS11R double mutations. This altered plasmid does not contain the T<sub>1</sub>T<sub>2</sub> transcription terminator, and does carry the helix 2 cassette.

#### EXAMPLE 14

#### STABILITY PROFILES OF MODIFIED RECOMBINANT SOMATOTROPINS

The procedure described to determine stability profiles is as follows. The concentrated solution of the recombinant (animal) somatotropin derivative (up to 100mg/ml) in phosphate buffered saline pH7.4 (NaH<sub>2</sub>PO<sub>4</sub>·H<sub>2</sub>O 3.45gm, Na<sub>2</sub>HPO<sub>4</sub> 3.55 gm, NaCl 9.50 gm dissolved in distilled water 1000 ml) is prepared. This is filtered through a millipore sterile Millex-0.22µm filter unit and 0.1 ml aliquots placed into tubes. These are placed in a 43°C oven and removed at the required intervals. The contents are then diluted with phosphate buffered saline. The supernatant is assayed for monomer and dimer content by HPLC. A mass balance is done. Any precipitated material is recorded. Results are compared with the initial concentrations and a stability profile documented.

Alternately, a somatotropin derivative exhibiting poor solubility at pH7.4 is dissolved at a less preferred pH (4-10) or is evaluated as a suspension.

The results of solution stability studies for the altered rpST proteins are summarized in Table III.

TABLE III

rpST MUTANT PROTEIN SOLUBILITY IN VITRO		
Mutation	% Soluble	Days Incubated at 43°C
A34	32	14
I122L + A34	44	14
E34	70.0(3) 67	14 17
I122L + E34	62.0(2) 66.3(3)	14 17
A6TS11R + E34	68.5(2)	14
P8TS11R + E34	62	14
A6TS11R + I122L + E34	36	14
P8TS11R + I122L + E34	2	14
L118K + A34	0	3
E119LQ123L + A34	0	3
L115A + A34	0	3
L118A + A34	10	7
M126A + A34	18	3
L118A1122L + A34	2	7
I122LM126A + A34	22(2)	19
S81,87L + A34	0	3
S81,87L + E119LQ123L + A34	0	7
S81,87L + I122L + A34	8	7
S81,87L + M126A + A34	0	3

Percent solubility is expressed as the fraction of the total remaining in solution x 100. (See Example 14). Where more than one determination is made, an average % solubility is presented, and the number of independent determinations is given in parentheses. The rpST mutants are present in either the A34 or E34 backgrounds. A34 rpST contains alanine, instead of cysteine, at positions 183 and 191. E34 rpST contains glutamate instead of cysteine at positions 183 and 191.

## EXAMPLE 15

5 HYPOX RAT TEST METHOD FOR DETERMINING THE GROWTH ENHANCEMENT OF ANIMALS RECEIVING RECOMBINANT (ANIMAL) SOMATOTROPIN DERIVATIVE

The efficacy of the recombinant animal somatotropin derivatives of the present invention for altering the growth rate of animals is determined utilizing the hypophysectomized (hypox) rat assay. The hypophysectomized rat does not produce its own somatotropin and is sensitive to injected somatotropin. The response measured is growth over a period of time such as 10 days and is presented in Table IV as percent of the biological activity of the rpST positive control, which is included in every trial.

TABLE IV

15

BIOLOGICAL DATA (HYPOX RAT, RRA) AND THERMAL STABILITY FOR rpST MUTANT PROTEINS			
Mutation(s)	Hypox rat <sup>a</sup>	RRA <sup>b</sup>	T <sub>m</sub> (°C)
A34	112.8	173.5	nd
I122L + A34	97.4	225.8	79
E34	90.52(5)	51.4(7)	62.0(6)
I122L + E34	66.66(5)	80.28(5)	62.67(5)
L115K	0.3	1.2	>83
L115K + E34	0.8	0.9	79
L118K	1.8	43.9	36
E119LQ123L	33.8	80.2	49
L115A	88.6	163	50
L118A	64(3)	49.5	57
M126A	100	122	55
L118AI122L	38.9	57.9	56
I122LM126A	66.25(2)	82.55(2)	63
S81,87L	46.9	194	40
S81,87L + E119LQ123L	40.4	177.9	38
S81,87L + I122L	71.3	165	47
S81,87L + M126A	79.7	186	47
L82,84Q	9.7(2)	3.4	none observe
K114R + E34	121.3	53.2	62
A6TS11R + E34	80.7(4)	135.0(4)	64.0(4)
P8TS11R + E34	129.7	78.5	65
A6TS11R + I122L + E34	116.7	112.8	61
P8TS11R + I122L + E34	127.9	89.3	64

<sup>a</sup>Hypox rat results are given as percent of the activity of the rpST standard used as the positive control.

45 <sup>b</sup>RRA-Liver radio-receptor assay results are given as percent of the activity observed with the rpST standard.

nd: not determined

Where more than one determination is made, an average is given, with the number of determinations given in parentheses.

50

## EXAMPLE 16

55 LIVER RADIO-RECEPTOR ASSAY FOR DETERMINING ABILITY OF ALTERED RECOMBINANT SOMATOTROPIN TO BIND TO SOMATOTROPIN RECEPTOR IN VITRO

An *in vitro* radioreceptor assay is employed to assess the ability of the recombinant somatotropins of the present invention to compete with <sup>125</sup>I-rpST for binding to somatotropin receptor from purified liver

membranes. The results of these assays are given as percent rpST binding and are presented in Table IV.

#### EXAMPLE 17

##### 5 NITROGEN BALANCE EXPERIMENTS CONDUCTED WITH rpST MUTANT I122L + E34

To evaluate biological activity of altered rpST proteins carrying the I122L mutation *in vivo*, a nitrogen balance study is conducted as described in EP355460. Subcutaneous administration of pST to growing pigs increases the quantity of protein deposited in the body, primarily as muscle. The use of a nitrogen balance  
 10 test provides a measure of the change in amount of protein deposited by an animal. Since protein contains a fixed amount of nitrogen, analyzing feedstuffs and excreta for nitrogen provide an accurate estimate of the status of protein deposition. Thus, nitrogen balance is a measure of the amount of nitrogen consumed in the feed and the amount excreted in the urine and feces with the amount retained (deposited) calculated by difference. Nitrogen retention is most accurately estimated as the amount of nitrogen retained as a  
 15 percentage of the amount of nitrogen digested (nitrogen consumed minus fecal nitrogen). In this study, the cysteine residues at positions 183 and 191 of the rpST I122L variant have been replaced with glutamic acid. The results of this analysis demonstrate full biological activity of the altered rpST molecule relative to the rpST control.

#### 20 EXAMPLE 18

##### DETERMINATION OF THERMAL STABILITY USING FLUORESCENCE SPECTROSCOPY

The thermal stability of altered rpST is inferred from measuring the intrinsic tryptophan fluorescence as  
 25 a function of temperature. The rpST molecule contains a single tryptophan residue, whose intrinsic fluorescence is severely quenched in the "native state". Increasing temperature, or decreasing pH, causes a characteristic increase in fluorescence, which is presumably due to a loss of structure at least in the immediate vicinity of the otherwise buried tryptophan residue. A "melting profile" of fluorescence versus increasing temperature reveals a sigmoidal curve, in which fluorescence remains quenched up until a  
 30 temperature that is characteristic for a given rpST derivative. A sharp increase in fluorescence over a rather narrow temperature range then ensues. The temperature that defines the midpoint of this increase in fluorescence is designated  $T_{(m)}$  and is a reflection of the protein's thermal stability. The  $T_{(m)}$  of the rpST of the present invention is determined by the method of Burger, et al 1966, except that 295 nm is used as the excitation wavelength and the emission fluorescence is read using a 355 nm cut off filter. The  $T_{(m)}$  of the  
 35 rpST of the present invention is summarized in Table IV. These data reveal a marked increase in  $T_{(m)}$  of 79°C for I122L.

#### EXAMPLE 19

##### 40 GENERATION OF THE I122L MUTATION BY THE POLYMERASE CHAIN REACTION METHOD

The I122L mutation is introduced into the rpST gene by site-directed mutagenesis utilizing an application of polymerase chain reaction technology as described by Sarkar and Sommer 1990, incorporated herein by reference. The three oligonucleotide primers used are listed in Table I and include  
 45 oligonucleotides SacI293, L120-3 and PvuII634. The rpST gene-containing EcoRI/HindIII fragment from plasmid pGEMpST-SX is used as the template. Fifteen cycles of polymerase chain reaction (hereafter referred to as PCR) is performed on 1 ng template rpST DNA with 1  $\mu$ M each of the L120-3 and PvuII634 oligonucleotide primers, dNTP's and Tag DNA polymerase, as specified by the manufacturer. This reaction results in a 227 bp DNA fragment, which contains the I122L mutation. This fragment is purified by agarose  
 50 gel electrophoresis and is used as a PCR primer in combination with oligonucleotide primer SacI293 and the rpsT-containing EcoRI/HindIII template fragment in 15 additional cycles of PCR. The resultant 361 bp fragment is cleaved with restriction endonucleases SacI and PvuII, purified by agarose gel electrophoresis and ligated into the large gel-purified, SacI/PvuII pGEMpST-SX DNA fragment. The ligation mixture is transformed into HB101 competent cells. Plasmid DNA of the resulting transformants is screened for the  
 55 presence of the I122L mutation precisely as described for L118E, except that oligonucleotide L120-3 is used as the radio-labelled hybridization probe and only one round of screening is performed. The presence of the I122L mutation and the absence of additional mutations introduced by the PCR reactions is confirmed by DNA sequence analysis. The plasmid bearing this mutation is designated pGEMpST-SX-I122L<sub>PCR</sub>.

## EXAMPLE 20

## RECONSTRUCTION OF rpST MUTATION I122L INTO A PLASMID SUITABLE FOR EXPRESSION IN YEAST

- 5 In order to express the I122L mutation-bearing rpST gene in the yeast, *Saccharomyces cerevisiae*, the rpST encoding DNA must be operably linked to a promoter sequence derived from this yeast. The ends of the small rpST-bearing NdeI/HindIII fragment from pOpST-SXE-I122L are made flush by treatment of this DNA with the large Klenow fragment of DNA polymerase I after the plasmid is cleaved with NdeI and
- 10 HindIII. This fragment is purified by gel electrophoresis and joined with the large Sall/SphI fragment of plasmid is YEp352-2. The ends of this latter fragment are made flush by treatment with S1 nuclease. This plasmid is a YEp352-derivative, which has been modified to additionally contain the divergent GAL1/GAL10 promoter (Johnston and Davis, 1984), and the 3' untranslated region derived from the STE7 gene (Teague, et al, 1986). The resulting plasmid is designated YEp352-pST-I122L (Figure 5).
- 15 Expression of this rpST variant in yeast is accomplished by culturing yeast cells transformed with this plasmid in a synthetic complete medium (Sherman, Fink and Hicks, 1986) that lacks uracil and contains 2% galactose as the sole carbon source at 30°C for several hours, or however necessary to achieve maximal rpST gene induction and rpST production. Although any yeast strain carrying a mutation in the URA3 gene can be used as the host, it is preferable to employ a yeast strain that is deficient in protease production and
- 20 is GAL +, such as BJ5457 (genotype MAT $\alpha$  pep4::HIS3 prb1- $\Delta$  trp1 ura3-52 leu2- $\Delta$  his3- $\Delta$  lys2-801 can1 GAL +). This strain is deposited with the Yeast Genetic Stock Center, University of California, BJ5457.

## BIBLIOGRAPHY

- 25 1. Abdel-Meguid et al. (1981), *Proc. Natl. Acad. Sci. USA* 84, 6434-6437.  
 2. Brems (1988), *Biochemistry* 27, 4541-4546.  
 3. Brems et al. (1986), *Biochemistry* 25, 6539-6543.  
 4. Brems et al (1988), *Proc. Natl. Acad. Sci. USA* 84, 3367-3371.  
 5. Burger, H.G., Edelhoich, H. and Condliffe, P.G., (1966) *Endocrinology* 78, 98-102 .
- 30 6. Chen, W.Y. et al. (1990), *Proc. Natl. Acad. Sci USA* 87, 5061-5065 .  
 7. Johnston and Davis (1984) *Molecular and Cellular Biology* 4, 1440-1448 .  
 8. Sarkar and Sommer (1990), *Biotechniques* 8, 404-407 .  
 9. Teague et al (1986), *Proc. Nat. Acad. Sci USA* 83, 7371-7375.  
 10. Sherman, F. Fink, G. R. and Hicks, J.B. (1986), "Laboratory Course Material for Methods in Yeast
- 35 Genetics" Cold Spring Harbor Laboratory, Cold Spring Harbor, New York, 163-168.

40

45

50

55

SEQUENCE LISTING

(1) GENERAL INFORMATION:

5 (i) APPLICANT: Meir Fischer, Michael Richard Lebens,  
Deborah Tardy Chaleff

10 (ii) TITLE OF INVENTION: Somatotropins with  
Alterations in the Alpha-Helix 1 Region, and  
Combinations with Other Mutations

(iii) NUMBER OF SEQUENCES: 1

15 (iv) CORRESPONDENCE ADDRESS:

(A) ADDRESSEE: John P. White, Cooper & Dunham

(B) STREET: 30 Rockefeller Plaza

20 (C) CITY: New York

(D) STATE: New York

25 (E) COUNTRY: United States of America

(F) ZIP: 10112

(v) COMPUTER READABLE FORM:

30 (A) MEDIUM TYPE: 3.5" Double Sided Hard Disk

(B) COMPUTER: IBM PC AT

35 (C) OPERATING SYSTEM: MS-DOS

(D) SOFTWARE: ASCII converted from IBM  
Displaywrite 4

(vi) CURRENT APPLICATION DATA:

(A) APPLICATION NUMBER:

(B) FILING DATE:

(C) CLASSIFICATION:

(vii) PRIOR APPLICATION DATA:

(A) APPLICATION NUMBER:

(B) FILING DATE:

(viii) ATTORNEY/AGENT INFORMATION:

(A) NAME: White, John P.

(B) REGISTRATION NUMBER: 28,678

(C) REFERENCE/DOCKET NUMBER: 38360/JPW/LSW

(ix) TELECOMMUNICATION INFORMATION:

(A) TELEPHONE: 212 977 9550

(B) TELEFAX: 212 664 0525

(C) TELEX:

(2) INFORMATION FOR SEQ ID NO: 1:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 193 base pair

5

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

10

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE:

15

(iii) HYPOTHETICAL:

20

(iv) ANTI-SENSE:

(v) FRAGMENT TYPE:

25

(vi) ORIGINAL SOURCE:

(A) ORGANISM:

30

(B) STRAIN:

(C) INDIVIDUAL ISOLATE:

35

(D) DEVELOPMENTAL STAGE:

40

(E) HAPLOTYPE:

(F) TISSUE TYPE:

45

(G) CELL TYPE:

50

(H) CELL LINE:

(I) ORGANELLE:

55



(vii) IMMEDIATE SOURCE:

5

(A) LIBRARY:

(B) CLONE:

10

(viii) POSITION IN GENOME:

15

(A) CHROMOSOME/SEGMENT:

(B) MAP POSITION:

20

(C) UNITS:

(ix) FEATURE:

25

(A) NAME/KEY:

(B) LOCATION:

30

(C) IDENTIFICATION METHOD:

35

(D) OTHER INFORMATION:

(x) PUBLICATION INFORMATION:

40

(A) AUTHORS:

(B) TITLE:

45

(C) JOURNAL:

50

(D) VOLUME:

(E) ISSUE:

55

(F) PAGES:

(G) DATE:

5

(H) DOCUMENT NUMBER:

(I) FILING DATE:

10

(J) PUBLICATION DATE:

(K) RELEVANT RESIDUES:

15

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 1:

20

ATG GAT CAA TTC CCA GCC ATG CCC TTG TCC AGC CTA 36

Met Asp Gln Phe Pro Ala Met Pro Leu Ser Ser Leu

25

1

5

10

TTT GCC AAC GCC GTG CTC CGG GCC CAG CAC CTG CAC 72

Phe Ala Asn Ala Val Leu Arg Ala Gln His Leu His

30

15

20

CAA CTG GCT GCC GAC ACC TAC AAG GAG TTT GAG CGC 108

35

Gln Leu Ala Ala Asp Thr Tyr Lys Glu Phe Glu Arg

25

30

35

GCC TAC ATC CCG GAG GGA CAG AGG TAC TCC ATC CAG 144

40

Ala Tyr Ile Pro Glu Gly Gln Arg Tyr Ser Ile Gln

40

45

AAC GCC CAG GCT GCC TTC TGC TTC TCG GAG ACC ATC 180

45

Asn Ala Gln Ala Ala Phe Cys Phe Ser Glu Thr Ile

50

55

60

50

CCG GCC CCC ACG GGC AAG GAC GAG GCC CAG CAG AGA 216

Pro Ala Pro Thr Gly Lys Asp Glu Ala Gln Gln Arg

55

65

70

5	TCG GAC GTG GAG CTG CTG CGC TTC TCG CTG CTG CTC Ser Asp Val Glu Leu Leu Arg Phe Ser Leu Leu Leu	252
	75 80	
10	ATC CAG TCG TGG CTC GGG CCC GTG CAG TTC CTC AGC Ile Gln Ser Trp Leu Gly Pro Val Gln Phe Leu Ser	288
	85 90 95	
15	AGG GTC TTC ACC AAC AGC CTG GTG TTT GGC ACC TCA Arg Val Phe Thr Asn Ser Leu Val Phe Gly Thr Ser	324
	100 105	
20	GAC CGC GTC TAC GAG AAG CTG AAG GAC CTG GAG GAG Asp Arg Val Tyr Glu Lys Leu Lys Asp Leu Glu Glu	360
	110 115 120	
25	GGC ATC CAG GCC CTG ATG CGG GAG CTG GAG GAT GGC Gly Ile Gln Ala Leu Met Arg Glu Leu Glu Asp Gly	396
	125 130	
30	AGC CCC CGG GCA GGA CAG ATC CTC AAG CAA ACC TAC Ser Pro Arg Ala Gly Gln Ile Leu Lys Gln Thr Tyr	432
35	135 140	
40	GAC AAA TTT GAC ACA AAC TTG CGC AGT GAT GAC GCG Asp Lys Phe Asp Thr Asn Leu Arg Ser Asp Asp Ala	468
	145 150 155	
45	CTG CTT AAG AAC TAC GGG CTG CTC TCC TGC TTC AAG Leu Leu Lys Asn Tyr Gly Leu Leu Ser Cys Phe Lys	504
	160 165	
50	AAG GAC CTG CAC AAG GCT GAG ACA TAC CTG CGG GTC Lys Asp Leu His Lys Ala Glu Thr Tyr Leu Arg Val	540
	170 175 180	
55		

ATG AAG TGT CGC CGC TTC GTG GAG AGC AGC TGT GCC 576  
 Met Lys Cys Arg Arg Phe Val Glu Ser Ser Cys Ala

5

185

190

TTC

579

Phe

10

### Claims

- 15 1. A somatotropin comprising: a mutation or a double mutation of said somatotropin in the alpha-helix 1 region thereby making said somatotropin more soluble than the native form of said somatotropin while maintaining biological activity in a sustained release formulation.
- 20 2. The somatotropin of Claim 1, wherein said somatotropin is human, bovine, porcine, ovine, caprine, equine, fish or avian somatotropin.
3. The somatotropin of Claim 2, wherein said alpha-helix 1 mutation or double mutation is A6T, A14D, S11RA14D, Q21HH22R, A6TS11R or P8TS11R.
- 25 4. The somatotropin according to Claim 3, wherein said somatotropin is human, bovine, porcine, ovine, caprine, equine, fish or avian somatotropin.
5. The somatotropins according to Claim 4, wherein said alpha-helix 1 mutations comprises: A6T, A14D, S11RA14D, Q21HH22R, A6TS11R or P8TS11R.
- 30 6. A somatotropin comprising: a mutation of said somatotropin in the alpha-helix 3 region and a mutation or double mutation in the alpha-helix 1 region thereby making said somatotropin more soluble than the native form of said somatotropin while maintaining biological activity in a sustained release formulation.
- 35 7. The somatotropin according to Claim 6, wherein said somatotropin is human, bovine, porcine, ovine, caprine, equine, fish or avian somatotropin.
8. The somatotropin according to Claim 7, wherein said alpha-helix 3 mutation comprises: I122L, L115E, L115K, L115KL118E, L118E, L118T, L118K, L118EI122K, I122E, E119LQ123L, M126A, L118A, G121A, K114R, K116R, I122LM126A or I122LL118A.
- 40 9. The somatotropin according to Claim 8, wherein said alpha-helix 1 mutation is A6T, A14D, S11RA14D, Q21HH22R, A6TS11R or P8TS11R.
- 45 10. The somatotropin according to Claim 9, wherein said alpha-helix 3 mutation is I122L.
11. The somatotropin according to Claim 10, wherein said alpha-helix 1 double mutation is A6TS11R.
12. The somatotropin according to Claim 10, wherein said double mutation is P8TS11R.
- 50 13. The somatotropin according to Claim 11, wherein said somatotropin is porcine or bovine somatotropin.
14. The somatotropin according to Claim 12, wherein said somatotropin is porcine or bovine somatotropin.
- 55 15. The somatotropin according to Claim 1, wherein at least one of the four cysteine amino acid residues in said somatotropin is replaced, modified, eliminated or derivatized.
16. The somatotropin according to Claim 15, wherein of the four (4) cysteine, two in the small loop and two

in the large loop, at least one (1) is replaced by the amino acids individually selected from arginine, lysine, aspartic acid, glutamic acid, asparagine, glutamine, histidine, alanine, glycine, isoleucine, leucine, valine, phenylalanine, tryptophan, tyrosine, methionine, serine, threonine or proline.


- 5 17. The somatotropin according to Claim 16, wherein said amino acids are individually selected from glutamic acid or alanine.
18. The somatotropin according to Claim 17, wherein the cysteines at positions 183 and 191 are replaced with glutamic acid.
- 10 19. The somatotropin according to Claim 17, wherein the cysteines at positions 183 and 191 are replaced with alanine.
20. The somatotropin according to Claim 18, wherein said somatotropin is human, bovine, porcine, ovine, 15 caprine, equine, fish or avian somatotropin.
21. The somatotropin according to Claim 19, wherein said somatotropin is human, bovine, porcine, ovine, caprine, equine, fish or avian somatotropin.
- 20 22. The somatotropin according to Claim 20, wherein said alpha-helix 1 mutation or double mutation is A6T, A14D, S11RA14D, Q21HH22R, A6TS11R or P8TS11R.
23. The somatotropin according to Claim 21, wherein said alpha-helix 1 mutation or double mutation is A6T, A14D, S11RA14D, Q21HH22R, A6TS11R or P8TS11R.
- 25 24. The somatotropin according to Claim 6, wherein at least one of the four cysteine amino acid residues in said somatotropin is replaced, modified, eliminated or derivatized.
25. The somatotropin according to Claim 24, wherein of the four (4) cysteines two in the small loop and two 30 in the large loop, at least (1) is replaced by the amino acids individually selected from arginine, lysine, aspartic acid, glutamic acid, asparagine, glutamine, histidine, alanine, glycine, isoleucine, leucine, valine, phenylalanine, tryptophan, tyrosine, methionine, serine, threonine or proline.
26. The somatotropin according to Claim 25, wherein said amino acids are individually selected from 35 glutamic acid or alanine.
27. The somatotropin according to Claim 26, wherein the cysteines at positions 183 and 191 are replaced with glutamic acid.
- 40 28. The somatotropin according to Claim 27, wherein said alpha-helix 3 mutation comprises: I122L, L115D, L115K, L115KL118E, L118E, L118T, L118K, L118EI122K, I122E, E119LQ123L, M126A, L118A, G121A, K114R, K116R, I122LM126A or I122LL118A.
29. The somatotropin according to Claim 28, wherein said alpha-helix 1 mutation is A6T, A14OD, 45 S11RA14D, Q21HH22R, A6TS11R or P8TS11R.
30. The somatotropin according to Claim 29, wherein said alpha-helix 3 mutation is I122L.
31. The somatotropin according to Claim 30, wherein said alpha-helix 1 mutation is A6TS11R.
- 50 32. The somatotropin according to Claim 30, wherein said alpha-helix 1 mutation is P8TS11R.
33. The somatotropin according to Claim 15, wherein of four (4) cysteines, two in the small loop and two in the large loop, at least one (1) is deleted.
- 55 34. The somatotropin according to Claim 15 wherein four cysteines are modified to cysteic acid.
35. The somatotropin according to Claim 33, wherein said somatotropin is human, bovine, porcine, ovine,

caprine, equine, fish or avian somatotropin.

36. The somatotropin according to Claim 34, wherein said somatotropin is human, bovine, porcine, ovine, caprine, equine, fish or avian somatotropin.
37. The somatotropin according to claim 24, wherein of the four (4) cysteines, two in the small loop and two in the large loop, at least one (1) is eliminated.
38. The somatotropin according to Claim 37, wherein said alpha-helix 3 mutation comprises: I122L, L115D, L115K, L115KL118E, L118E, L118T, L118K, L118EI122K, I122E, E119LQ123L, M126A, L118A, G121A, K114R, K116R, I122LM126A or I122LL118A.
39. The somatotropin according to Claim 38, wherein said alpha-helix 1 mutation is A6T, A14D, S11RA14D, Q21HH22R, A6TS11R or P8TS11R.
40. The somatotropin according to Claim 39, wherein said alpha-helix 3 mutation is I122L.
41. The somatotropin according to Claim 40, wherein said alpha-helix 1 mutation is A6TS11R.
42. The somatotropin according to Claim 40, wherein said alpha-helix 1 mutation is P8TS11R.
43. The somatotropin according to Claim 24, wherein the four cysteines are modified to cysteic acid.
44. The somatotropin according to claim 43, wherein said alpha-helix 3 mutation comprises: I122L, L115D, L115K, L115KL118E, L118E, L118T, L118K, L118EI122K, I122E, E119LQ123L, M126A, L118A, G121A, K114R, K116R, I122LM126A or I122LL118A.
45. The somatotropin according to Claim 44, wherein said alpha-helix 1 mutation is A6T, A14OD, S11RA14D, Q21HH22R, A6TS11R or P8TS11R.
46. The somatotropin according to Claim 45, wherein said alpha-helix 3 mutation is I122L.
47. The somatotropin according to Claim 46, wherein said alpha-helix 1 mutation is A6TS11R.
48. The somatotropin according to Claim 46, wherein said alpha-helix 1 mutation is P8TS11R.

Figure 1

Restriction map of rpST gene



Regions of rpST gene subjected to site-directed mutagenesis are shown below the rpST restriction map and numbered 1 (helix 1), 2 (helix 2), 3 (helix 3) and 4 (small 100p cys-encoding DNA, as in EP355460)

- R1 = EcoRI
- N = NdeI
- B = BssHII
- S = SacI
- X = XbaI
- Sm = SmaI
- H = HindIII

Figure 2






Figure 3






Figure 4



226 Expression vector for reconstruction of rpST mutations and expression in *E. coli*. The cII ribosome binding site is located between the EcoRI and NdeI restriction sites. The translational initiation codon for rpST is embedded in the NdeI site.

Figure 5



Yeast expression plasmid YEp352-pST-I122L.





Europäisches Patentamt  
European Patent Office  
Office européen des brevets



Publication number: **0 496 973 A3**

**EUROPEAN PATENT APPLICATION**

Application number: **91120396.6**

Int. Cl.<sup>5</sup>: **C12N 15/18, C07K 13/00,  
C07K 3/08**

Date of filing: **28.11.91**

Priority: **30.11.90 US 621656**

Date of publication of application:  
**05.08.92 Bulletin 92/32**

Designated Contracting States:  
**AT BE CH DE DK ES FR GB GR IT LI LU NL SE**

Date of deferred publication of the search report:  
**24.02.93 Bulletin 93/08**

Applicant: **BIO-TECHNOLOGY GENERAL  
CORPORATION**  
**1250 Broadway**  
**New York NY 10001(US)**  
Applicant: **AMERICAN CYANAMID COMPANY**  
**1937 West Main Street P.O. Box 60**  
**Stamford Connecticut 06904-0060(US)**

Inventor: **Fischer, Meir**  
**12 Gorodesky Street**  
**Rehovot(IL)**  
Inventor: **Lebens, Michael Richard**  
**19A Hehalutz Street**  
**Jerusalem(IL)**  
Inventor: **Chaleff, Deborah Tardy**  
**31 Arvida Drive**  
**Pennington, Mercer, New Jersey 08534(US)**

Representative: **Wächtershäuser, Günter, Dr.**  
**Tal 29**  
**W-8000 München 2 (DE)**

**Somatotropins with alterations in the alpha-helix 1 region, and combinations with other mutations.**

The present invention relates to somatotropin analogues with amino acid changes in the alpha-helix 1 regions of said somatotropins, alone or in combination with mutations in the alpha-helix 3 and/or alpha-helix 2 regions, plus combinations with other changes to the native amino acid sequence of somatotropins. The resulting analogues are stable for formulation in sustained release formulations, while maintaining biological activity. Further, methods for conducting site-directed mutagenesis on DNA encoding proteins and/or polypeptide also are provided.

**EP 0 496 973 A3**



European Patent  
Office

# EUROPEAN SEARCH REPORT

Application Number

EP 91 12 0396

DOCUMENTS CONSIDERED TO BE RELEVANT			
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	CLASSIFICATION OF THE APPLICATION (Int. Cl.5)
T	PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA. vol. 84, September 1987, WASHINGTON US pages 6434 - 6437 SHERIN S. ABDEL-MEGUID ET AL 'Three dimensionnal stucture of a genetically engineerd variant of porcine growth hormone'		C12N15/18 C07K13/00 C07K3/08
D,A	EP-A-0 355 460 (AMERICAN CYANAMID COMPANY)  * claims *	15-21, 24-27, 33-37,43	
A	SCIENCE vol. 244, 2 June 1989, LANCASTER, PA US pages 1081 - 1085 B. C. CUNNINGHAM ET AL 'High resolution epitope mapping of hGH-receptor interactions by alanine-scanning mutagenesis' * abstract; table 1 *	1-2	
A	WO-A-9 004 788 (GENENTECH, INC.) * the whole document especially table III *	1-2	
The present search report has been drawn up for all claims			
Place of search THE HAGUE		Date of completion of the search 18 DECEMBER 1992	Examiner LE CORNEC N.D.R.
<b>CATEGORY OF CITED DOCUMENTS</b> X : particularly relevant if taken alone Y : particularly relevant if combined with another document of the same category A : technological background O : non-written disclosure P : intermediate document  T : theory or principle underlying the invention E : earlier patent document, but published on, or after the filing date D : document cited in the application L : document cited for other reasons * : member of the same patent family, corresponding document			

EPO FORM 1503 03.82 (P0401)